Publications

Suppression of cancer relapse and metastasis by inhibiting cancer stemness
Youzhi Li, Harry A. Rogoff, Sarah Keates, Yuan Gao, Sylaja Murikipudi, Keith Mikule, David Leggett, Wei Li, Arthur B. Pardee, and Chiang J. Li December 23, 2014 PNAS 2015 ; Published on February 10, 2015
Cancer Stem Cells: Current Perspectives, Future Directions—a supplement to Oncology Times.
Interviews with: Max S Wicha, MD, and Jaffer Ajani, MD. This supplement provides current insights into the role of CSCs in tumor initiation, progression, and metastasis, with a focus on gastric and gastroesophageal tumors. The potential for inhibition of CSC signaling pathways is reviewed.
Cancer Stem Cells: The Promise and the Potential
This supplement updates clinicians on the accumulated evidence characterizing the role of CSCs in tumor initiation, heterogeneity, therapy resistance, and recurrence and metastasis, as well as the therapeutic potential of targeting CSCs. Jaffer Ajani, Shumei Song, Howard Hochster, and Ira Steinberg, guest editors.

Abstracts and Presentations

The following scientific and clinical research was published or presented at meetings hosted by the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).

MeetingTitle
The 2017 ESMO Congress, Barcelona, SpainCanStem303C Trial: A Phase III Study of Napabucasin in Combination with 5-Fluorouracil (5-FU), Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (mCRC). (Poster)
The 2017 ESMO Congress, Barcelona, SpainCanStem111P Trial: A Phase III Study of Napabucasin plus nab-Paclitaxel (nab-PTX) with Gemcitabine (gem) in Adult Patients with Metastatic Pancreatic Adenocarcinoma (mPDAC) (Poster)
The 2017 ESMO Congress, Barcelona, SpainPhase 1b/II Study of Cancer Stemness Inhibitor Napabucasin in Combination with FOLFIRI +/- bevacizumab (bev) in Metastatic Colorectal Cancer (mCRC) Patients (pts) (Poster)
The 2017 ESMO Congress, Barcelona, SpainA Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin in Combination with Gemcitabine (gem) & Nab-paclitaxel (nabPTX) in Metastatic Pancreatic Adenocarcinoma (mPDAC) Patients (pts) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILA phase 1b/2 study of Amcasertib, a First-in-Class Cancer Stemness Kinase Inhibitor, in Advanced Adenoid Cystic Carcinoma (Abstract) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILA Phase 1b/2 study of Amcasertib, a First-in-Class Cancer Stemness Kinase Inhibitor in Advanced Head & Neck Cancer (Abstract) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILA Phase 2 Study of Napabucasin with Weekly Paclitaxel in Previously Treated Metastatic Breast Cancer (Abstract) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILA Phase 1b/2 Study of Napabucasin with Weekly Paclitaxel in Advanced, Previously Treated Platinum Resistant Ovarian Cancer (Abstract) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILA Phase 1b Study of Napabucasin plus Weekly Paclitaxel in Patients with Advanced Melanoma (Abstract) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILA Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BBI-608) in Combination with Gemcitabine (gem) & Nab-paclitaxel (nabPTX) in Metastatic Pancreatic Adenocarcinoma (mPDAC) Patients (pts) (Abstract) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILA Phase 1b/2 Study of Napabucasin with Weekly Paclitaxel in Advanced, Previously Treated Non-Squamous Non-Small Cell Lung Cancer (Abstract) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILPhase 1b/II Study of Cancer Stemness Inhibitor Napabucasin (BBI-608) in Combination with FOLFIRI +/- Bevacizumab (bev) in Metastatic Colorectal Cancer (mCRC) Patients (pts) (Abstract) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILBBI608-503-103HCC: A Phase Ib/II Clinical Study of Napabucasin (BBI608) in Combination with Sorafenib or Amcasertib (BBI503) in Combination with Sorafenib(Sor) in Adult Patients with Hepatocellular Carcinoma (HCC) (Abstract) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILCanStem111P trial: A Phase III Study of Napabucasin (BBI-608) plus nab-Paclitaxel (nab-PTX) with Gemcitabine (gem) in Adult Patients with Metastatic Pancreatic Adenocarcinoma (mPDAC). (Abstract) (Poster)
The 2017 ASCO Annual Meeting, Chicago, ILCanStem303C trial: A Phase III Study of Napabucasin (BBI-608) in Combination with 5-Fluorouracil (5-FU), Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (mCRC) (Abstract) (Poster)

Join Our Team

We are looking for motivated, passionate and skilled scientists and commercial team members.

Learn More